Additionally, the associations between visfatin -3187G>A polymorphisms and the risk of CHB, HBV-LC, and HBV-HCC were not statistically significant, therefore, the variants of visfatin -3187G>A did not contribute to HBV-related liver diseases in this population. Here, NAMPT is linked to hepatocellular carcinoma.